Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination.
Journal: Clinical pharmacology and therapeutics
Published: October 01, 2025
Provider perspectives and experiences with initial implementation of medication abortion in a California public university health center: A qualitative study.
Journal: Journal of American college health : J of ACH
Published: September 04, 2025
Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC.
Journal: Molecular cancer therapeutics
Published: April 18, 2025
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Journal: Cancer research
Published: January 27, 2023
Showing 1-5 of 5
Last Updated: 09/26/2026